Hepatology Highlights

Adam Buckholz, Robert S. Brown, Hirsh Trivedi, Muzammil M. Khan, Hira Hanif, Daryl T.Y. Lau, Amneet Hans, Giorgio Roccaro, Joseph F. Pisa, Nidhi Jalan‐Sakrikar, Robert E. Schwartz, Nicholas W. Russo, Tejasav S. Sehrawat, Enis Kostallari, Adebowale O. Bamidele, Gopanandan Parthasarathy – 11 February 2021

American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease

Oren K. Fix, Emily A. Blumberg, Kyong‐Mi Chang, Jaime Chu, Raymond T. Chung, Elizabeth K. Goacher, Bilal Hameed, Daniel R. Kaul, Laura M. Kulik, Ryan M. Kwok, Brendan M. McGuire, David C. Mulligan, Jennifer C. Price, Nancy S. Reau, K. Rajender Reddy, Andrew Reynolds, Hugo R. Rosen, Mark W. Russo, Michael L. Schilsky, Elizabeth C. Verna, John W. Ward, Robert J.

coreNASH: Multi‐stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment

Elizabeth Clearfield, Veronica Miller, Joseph Nadglowski, Katherine Barradas, Jennifer Al Naber, Arun J. Sanyal, Brent A. Neuschwander‐Tetri, Donna A. Messner, the coreNASH Panel – 11 February 2021 – The increasing prevalence and burden of nonalcoholic steatohepatitis (NASH) has spurred the development of new treatments and a need to consider outcomes used for NASH treatment decision making. Development of a NASH core outcome set (COS) can help prioritize outcomes of highest importance by incorporating the perspectives from a variety of decision makers.

Subscribe to